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Lymphoma is a significant clinical entity because of its high incidence and 
complicated etiology and pathology. In this chapter, we discussed lymphoma in 
general and made focus in our previous studies in which we found unique features 
linking the interaction of EBV with sex steroid hormones in lymphoma cells. Sex 
steroid hormones included estrogen receptor and progesterone receptors that were 
investigated for their expression in malignant lymphoid cells. The localization of 
EBV in malignant lymphoid cells was also investigated. The two main types of  
lymphoma, Hodgkin Lymphoma, and non-Hodgkin lymphoma, were investi-
gated for the interaction of EBV with sex steroid hormones. Unique features were 
obtained in terms of a bridge-linking estrogen receptor with EBV in Hodgkin 
lymphoma and progesterone receptor with EBV in non-Hodgkin lymphoma. The 
interactions between EBV and lymphoma are classic, but the reasons beyond this 
are not well established. The results of our studies highlighted new features by 
the existence of expressed sex steroid receptors. We think that the dissociation of 
combination between sex steroid hormones and EBV bears the link to design new 
therapeutic strategies for lymphoma.
Keywords: lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, EBV,  
estrogen receptor, progesterone receptor
1. Introduction
1.1 An overview of lymphoma
Lymphoma is a term used to describe a group of lymphoproliferative malignant 
disorders that arise from lymphatic T- and B-cells [1]. Lymphoma is a group of 
malignancies that affect the lymphatic system [2]. The organs, tissues, and veins of 
the lymphatic system are part of the immune system and are important for battling 
disease and infection throughout the body [3]. When lymphocytes (the lymphatic 
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system’s white blood cells) become malignant, they proliferate abnormally, forming 
tumors and squeezing out healthy cells [3].
1.2 Types of lymphoma
Lymphoma has traditionally been divided into the two types: Hodgkin 
lymphoma (HL) and non-Hodgkin lymphoma (NHL). However, it is now recog-
nized that Hodgkin lymphoma is just one of many forms of lymphoma and that 
non-Hodgkin lymphoma is a largely meaningless phrase that encompasses all 
the disease’s other subtypes [4]. Non-Hodgkin lymphoma is a diverse collection 
of over 40 lymphoproliferative tumors with varying patterns of behavior and 
treatment responses [5]. Non-Hodgkin lymphoma has a lower prognosis than 
Hodgkin lymphoma, and prognosis is determined by histologic type, stage, and 
treatment [6].
There are over 70 different forms of lymphoma. Some grow slowly (sometimes 
known as low-grade or indolent), while others grow quickly (referred to as high-
grade or aggressive). Lymphoma has no known causes; however, several factors 
have been linked to an increased chance of having the disease. Hodgkin lymphoma 
and non-Hodgkin lymphoma are the two types of lymphomas. Hodgkin’s lymphoma 
is a type of cancer that affects the lymphatic system [7, 8].
2. Hodgkin lymphoma
HL is a type of lymphoma that affects roughly 9000 adults and children in the 
United States each year. Hodgkin lymphoma can occur anywhere lymphocytes 
are detected in the body. However, lymph nodes in the chest, neck, and beneath 
the arms are where it usually starts. HL differs from all other kinds of lymphoma 
in several ways, the most notable of which is the existence of a cell known as the 
Reed-Sternberg cell. A Reed-Sternberg cell is a big, unusual cell that does not 
defend the body against infection. It is called for the two scientists who found it. 
When it multiplies improperly, it creates a tumor within a lymph node and attracts 
inflammatory cells. Chemotherapy and/or radiation therapy may be used to treat 
HL. A stem cell transplant may be considered in some circumstances, particularly 
if the disease does not respond to early treatment or returns after an initial 
response [9].
Hodgkin lymphoma is also known as Hodgkin’s disease. It usually begins in a 
type of B cell that is found in the bone marrow. Hodgkin’s disease is considered 
one of the most curable forms of cancer, especially if it is diagnosed and treated 
early. Several types of treatment can be used against Hodgkin lymphoma, includ-
ing chemotherapy, immunotherapy, and stem cell transplantation [10]. Hodgkin 
lymphoma, often known as Hodgkin’s disease, is a type of lymphoma. It usually 
starts in a specific type of B cell located in the bone marrow. Hodgkin’s disease is 
one of the most treatable types of cancer, especially when detected and treated 
early [11]. Chemotherapy, immunotherapy, and stem cell transplantation are 
among the treatments available for Hodgkin lymphoma [12]. The presence of 
big aberrant tumor cells known as Hodgkin Reed-Sternberg cells distinguishes 
it. Hodgkin lymphoma can affect both children and adults; however, it is most 
diagnosed in young adults aged 20 to 34. Classic Hodgkin lymphoma and nodu-
lar lymphocyte-dominated Hodgkin lymphoma are the two primary subtypes 
of Hodgkin lymphoma. Classic Hodgkin lymphoma affects more than 90% of 
Hodgkin lymphoma cases [13].
3
Lymphoma and The Microenvironmental Cross-Talk between Sex Hormone Receptors and…
DOI: http://dx.doi.org/10.5772/intechopen.101055





• Hodgkin’s disease with lymphocyte depletion.
3. Non-Hodgkin lymphoma (NHL)
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of cancers, with 
B-cell origin in roughly 80% of cases (B-NHL). The presentation, clinical character-
istics, prognosis, and therapeutic response of B-NHL are all different. Diffuse large 
B-cell lymphoma (DLBCL) is the most frequent histologic subtype, accounting for 
about a third of cases in the United States, followed by follicular lymphoma, which 
accounts for about a quarter of occurrences ([16]). Other histologies are far less 
prevalent. Rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone 
are used to treat about 60% of DLBCL patients (R-CHOP). Most patients who 
relapse after or are refractory to initial therapy, on the other hand, succumb to their 
condition. Over the last decade, new therapeutic research has concentrated on mol-
ecules that target the cell surface, internal pathways, and the microenvironment, 
rather than cytotoxic chemotherapy drugs. The chimeric anti-CD20 monoclonal 
rituximab changed B-NHL therapy, extending survival in the majority of subtypes. 
However, resistance builds with time, necessitating the use of additional techniques 
aimed at other targets [17].
3.1 Primary central nervous system lymphoma (PCNSL)
PCNSL (primary central nervous system lymphoma) is an uncommon extra-
nodal non-Hodgkin lymphoma that is distinct from systemic diffuse large B-cell 
lymphomas. PCNSL is diagnosed at a median age of 65 years, and its prevalence 
is quickly increasing among the elderly. A total of 20% of all PCNSL patients are 
above the age of 80. Age, in particular, has been recognized as a poor prognostic 
factor for PCNSL. Elderly patients have a worse prognosis than younger patients 
and are more susceptible to iatrogenic toxicity; as a result, they are a distinct and 
vulnerable therapeutic class. The goal of this study was to provide a better under-
standing of the epidemiology, clinical features, diagnosis, prognosis, and therapy 
of PCNSL in the aged population by summarizing the current research. Notably, 
PCNSL is becoming more common in immunocompetent elderly patients, particu-
larly men. Imaging guided stereotactic biopsy is the gold standard for the diagnosis 
of CNSL. Certain biomarkers have been described that can aid establish a diagnosis 
when stereotactic biopsy is not possible or conclusive. Even though numerous prog-
nostic grading systems exist, and several prognostic markers have been discovered 
in PCNSL patients, the elderly have a very dismal prognosis. Furthermore, treating 
older individuals remains difficult; while a novel agent is unlikely to be utilized as a 
curative monotherapy, a combination of novel medicines with polychemotherapy 




Primary cutaneous lymphomas are a diverse category of extranodal non-
Hodgkin lymphomas that are restricted to the skin at the time of diagnosis [19]. 
In 2005 [20], the European Organization for Research and Treatment of Cancer 
(EORTC) and the World Health Organization (WHO) developed a cutaneous 
lymphoma consensus classification, which was recently updated [21]. Unlike nodal 
non-Hodgkin lymphoma, which is mostly B-cell originated, about 75% of primary 
cutaneous lymphomas are T-cell derived, with two-thirds of them being categorized 
as mycosis fungoides (MF) or Sézary syndrome (SS) [20, 22, 23]. According to 
the Surveillance, Epidemiology, and End Results (SEER) registry, the incidence of 
cutaneous T-cell lymphomas (CTCL) has been growing and is now 6.4 per million 
people, with the greatest incidence rates seen among men and African Americans 
[23]. When compared to non-Black individuals with MF, there are several major dis-
tinctions, including a female predominance, a younger age of onset, and probably 
worse results [24, 25]. While CTCL can arise in adolescents and young adults, it is a 
rare occurrence that is generally linked to histopathologic MF variations [26].
4. Lymphoma diagnosis
Lymphoma is diagnosed primarily through pathologic examination of an accept-
able tissue specimen in the right clinical situation, which may include morphologic, 
immunophenotypic, and cytogenetic studies as needed. Individual lymphomas 
are treated differently, necessitating an accurate and specific diagnosis to provide 
appropriate patient care [27]. The choice of biopsy procedure and place is a com-
mon practical challenge in patients suspected of having lymphoma. For initial diag-
nosis, surgical biopsy is preferred because the bigger tissue sample collected enables 
for investigation of processes that may involve the lymph node or extranodal mass 
in a variety of ways, as well as immunophenotypic, cytogenetic, and molecular 
analysis [28]. Fine needle aspiration may not allow for the study of histologic 
architecture, and it may not yield enough tissue for a thorough analysis, including 
the determination of biologic subtype [29]. In some cases, fine needle aspiration 
can confirm relapsed illness, although even in these cases, a core needle or surgical 
biopsy is preferred [30]. Core needle biopsy may allow for nodal architecture study, 
but it collects less tissue than surgical biopsy, perhaps missing a heterogeneous 
process and providing less material for thorough testing. Only in clinical scenarios 
where a surgical biopsy is not possible, a core needle biopsy is suggested for first 
diagnosis. Despite the WHO classification’s established definitions, an experienced 
hematopathologist will modify about one-fifth of lymphoma diagnoses, with the 
rate varied among the different forms of lymphoma [31, 32]. Expert pathology 
review is recommended and should be regarded standard of care because proper 
therapy is fundamentally dependent on correct pathologic diagnosis. When the 
diagnosis of lymphoma is unclear, medical imaging can be helpful in staging, but 
a definitive diagnosis of lymphoma and determination of the histologic subtype 
require pathological examination [27]. Though not conclusive, [18F]-fluoro-2-
deoxyglucose positron emission tomography (FDG-PET) imaging can identify 
aggressive from indolent lymphomas based on standard uptake value assessment 
and can help predict indolent lymphoma transformation (usually DLBCL). When 
transformation is suspected, PET can be used to choose an acceptable biopsy site 
where the standard uptake value is the highest and thus, transformation is most 
likely to be present; however, marked FDG avidity does not rule out transformation 
and does not eliminate the necessity for diagnostic biopsy [33].
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5. Viruses and lymphoma
Hepatitis C virus (HCV) is well known for its role in the etiology of chronic non-
A, non-B viral hepatitis, liver cirrhosis, and hepatocellular cancer; it has also been 
linked to a number of extra-hepatic “autoimmune” disease presentations. A causal 
link between HCV and non-Hodgkin lymphoma (NHL) was proposed just lately, 
and it has sparked a lot of research and debate. HCV appears to be implicated in 
the pathogenesis of at least a proportion of patients with NHL, based on epidemio-
logical data, developing scientific investigations, and clinical observations. HCV-
associated lymphomas are classified as marginal zone lymphoma (splenic, nodal, 
and extranodal), small lymphocytic lymphoma/chronic lymphocytic leukemia, 
lymphoplasmacytic lymphoma, lymphoplasmacytic lymphoma, and diffuse large 
B-cell lymphoma. Surprisingly, some HCV-associated NHLs appear to respond well 
to antiviral medication, giving clinical evidence for the link as well as the possibility 
of innovative therapeutic intervention [34].
Patients with HIV infection have a much higher rate of lymphoma than the 
normal population. Multiple factors appear to contribute to the increased risk of 
lymphoma, including the retrovirus’s transforming properties, the disease’s  
immunosuppression and cytokine dysregulation, and, most importantly, oppor-
tunistic infections with other lymphotrophic herpes viruses such as Epstein-Barr 
virus and human herpesvirus 8. Lymphomas are classified histologically into three 
groups: (1) those that occur in immunocompetent people, (2) those that occur 
more specifically in HIV-positive patients, and (3) those that occur in patients with 
various types of immunosuppression. The great majority of instances are aggressive 
lymphomas. They usually present with advanced stage, bulky cancer with a large 
tumor load and extranodal involvement. Clinical outcomes appear to be worse than 
those seen in the general population with similar severe lymphomas. The risk of 
developing lymphoma in the context of HIV infection has decreased, and the clini-
cal result has improved since the advent of highly active antiretroviral therapy [35].
Epstein-Barr virus (EBV) is a common virus that affects over 90% of the 
world’s population [36]. It was discovered to be linked to the development of 
EBV-associated lymphoproliferative diseases, hemophagocytic lymphohistiocytosis 
(HLH), and solid tumors, among other things, after being identified as an onco-
genic virus in a Burkitt’s lymphoma cell line [37]. In vitro infection and transforma-
tion of quiescent B cells into lymphoblastoid cell lines (LCLs) have proven EBV’s 
carcinogenic potential [36]. The ability of EBV to create a lifelong latent infection 
in B-lymphoma cells has been established as a key mechanism of EBV-induced 
lymphomagenesis. During EBV latency, the expression of highly immunogenic 
proteins is suppressed, while viral lytic proteins are increased, impairing antigen 
processing by infected cells, and destroying the cellular molecular signaling 
machinery and metabolism, allowing tumor cells to escape immune surveillance 
and grow and survive. The most frequent indolent and second most common non-
Hodgkin lymphoma subtype is follicular lymphoma (FL) [38]. Follicular lymphoma 
with EBV is a poorly understood disease that is infrequently reported [39]. Even 
though Asians have a higher incidence of EBV-associated cancers than Westerners, 
EBV-positive FL has been observed in the Chinese community on a rare basis. EBV 
is also the most frequent virus linked to HLH, a rare condition characterized by 
severe, life-threatening hyperinflammation. The decreased function of cytotoxic T 
lymphocytes and natural killer (NK) cells is the fundamental pathophysiology of 
HLH, resulting in uncontrolled immunological activation, hypercytokinemia, and 
macrophage proliferation. With a fatality rate of up to 50%, EBV-associated HLH is 
thought to be particularly common in Asia [40]. This may occur prior to, concur-
rently with, or after EBV-positive lymphoproliferative diseases [40]. T-cell and 
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NK-cell lymphomas account for the bulk of HLH-related cancers. The majority of 
B-cell lymphoma associated HLH cases have been observed in Asians [37].
6.  Microenvironmental interactions between lymphoma and EBV and 
sex hormones
The hypothesis of cross-talks between hormone receptors such as the estrogen 
receptor (ER) and the progesterone receptor (PR) in breast cancer has recently 
been revealed to have major effects on breast cancer. Many researches, including 
ours, have previously proven the associations of Epstein-Barr virus (EBV) with 
lymphoma. We wanted to see if “EBV cross-talk with sex hormones plays a role in 
dictating the kind of lymphoma, Hodgkin’s Lymphoma (HL) or non-Lymphoma 
Hodgkin’s (NHL)” in this work. In lymphoma patients representing HL and NHL, 
we looked at the expression of sex hormones, ER, and PR, as well as EBV. The 
expression of these biomarkers in lymphoma cases was assessed using immunoper-
oxidase staining. Our data revealed that EBV cross-talk with ER is strongly linked 
with HL (p < 0.05), but its cross-talk with PR is significantly associated with NHL 
(p < 0.05). The findings of this study suggest that EBV acts as the conductor of an 
orchestra, orchestrating the events of lymphoma through various interactions with 
sex hormones. This could pave the way for novel lymphoma treatment options [41].
Grywalska and Rolinski [42] highlighted in their review study that the Epstein-
Barr virus (EBV) has been linked to cancer pathogenesis. EBV is a member of the 
Herpesviridae family, and through the expression of multiple genes, it has devel-
oped ways to maintain the integrity of the viral genome and to escape from the 
host’s immune system during the latent stage of infection. This expression promotes 
the development of cancers. EBV can infect a wide range of cells, resulting in a 
variety of diseases, including B-cell lymphoma ([43]).
Several studies have reported the link between EBV infection and Hodgkin 
Lymphoma (HL) [42], and the presence of EBV in Hodgkin/Reed-Sternberg (HRS) 
was confirmed by researchers such as Weiss et al. [44] and Takeuchi et al. [45]. On the 
other hand, non-Hodgkin Lymphoma (NHL) includes a variety of lymphomas such as 
Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) [46, 47].
Dolcetti [48] stated in his work that EBV has the power to alter the microen-
vironment to make it more conducive to cell transformation. EBV can boost the 
synthesis of a variety of substances that help lymphoid cells grow and/or survive 
while also allowing them to avoid immune system reactions. There is a complicated 
interplay between EBV-infected lymphoid cells and the tumor microenvironment 
that has the therapeutic potential against EBV-driven lymphoid malignancies.
There are few therapeutic alternatives in the treatment of lymphomas caused by 
EBV that can affect the virus within malignant cells. However, in most instances, no 
variations in therapy options have been found based on whether EBV is present. As 
prospective therapeutic methods, existing therapeutic techniques have focused on 
interfering with biological components of EBV to target lymphomas associated with 
EBV [49]. EBV-explicit methodologies include reinforcing the antiviral-/antitumor-
resistant reaction with antibodies or EBV explicit cytotoxic T-lymphocytes, initiat-
ing lytic viral qualities to render tumor cells immune to antiviral treatments, and 
inhibiting downstream prosurvival or antiapoptotic pathways that may be triggered 
by dormant EBV proteins. EBV-explicit cytotoxic T-cell imbuements have shown 
to be effective in EBV-related post-transplantation lymphoproliferative disorder 
(EBVPTLD) and extending such assenting immunotherapies to additional EBV-
related cancers is a hot topic of investigation [49]. Other EBV-related lymphomas, in 
contrast to EBV-PTLD, have progressively constrained, less immunogenic kinds of 
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viral antigens to restoratively target with assenting immunotherapy. Furthermore, 
the threatening EBV-positive tumor cells of HL are dispersed during a thick layer 
of administrative T-cells, macrophages, and other cells, which may compromise 
supportive immunotherapy’s antitumor efficacy [50]. Continuous preclinical and 
clinical assessments are areas of continuous methodology to overcome these imped-
iments. Some emerging approaches to treating EBV-related lymphomas include 
combining specialists that trigger lytic viral replication with anti-herpes virus 
operators or using small particle inhibitors to block deterioration pathways that are 
constitutively triggered by EBV. EBV antibodies appear to be generally promising 
for the treatment or prevention of EBV-related cancers, as opposed to required EBV 
contamination avoidance [51]. Preliminary EBV vaccination trials in patients with 
residual or low-mass EBV-related malignancies, or for the counteractive effect of 
EBV-PTLD in EBV-seronegative patients awaiting strong organ transplantation, 
are moving forward ([52]). In many cases, the treatment of EBV-positive lympho-
mas is identical to that of EBV-negative lymphomas with similar histologies [53]. 
Special cases include experimental conventions and situations where a responsive 
immunotherapy method is available [54, 55]. When EBV-positive lymphomas 
appear in the context of immunosuppression, boosting the invulnerable deformities 
can help with lymphoma treatment [56, 57]. Antiretroviral treatment is routinely 
used in HIV-related lymphomas, but potential pharmaceutical interactions and the 
effects of chemotherapy on the ability to maintain HAART treatment in terms of 
sickness, heaving, and mucositis must be considered when antiretroviral treatment 
is planned [58, 59]. In any case, antiretroviral therapy alone is insufficient for the 
treatment of EBV-related lymphomas in HIV patients. This contrasts with AIDS-
related Kaposi sarcoma, where initiating antiretroviral medication in patients who 
are asymptomatic or insignificantly symptomatic and antiretrovirally innocent is 
frequently a regular practice [60, 61]. Select instances with EBV-PTLD may benefit 
from immunosuppressive reduction as a stand-alone treatment or as part of a 
therapeutic plan ([62, 63]). The therapeutic choices for lymphomas associated with 
EBV are like those for lymphomas that are EBV-negative. Existing therapy methods, 
on the other hand, include addressing biological elements of EBV and may require 
further research to be firmly established.
7. Conclusions
This study showed that new therapeutic strategies are of great potential based 
on the interactions of EBV, lymphoid malignant cells, and sex steroid hormones, 
ER or PR. Our studies showed interesting features by identifying the impacts of 
interaction of progesterone receptors with EBV leading to the development of NHL, 
while the interaction of EBV with ER led to the development of HL. These features 
are unique and give the bases of designing new therapeutic lines that inhibit the 
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